Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 6,113

Document Document Title
WO2006128268A8
The present invention describes functionalizeds derivatives of ethyl 6-N- alkyl and/or 6-N-aryl ureas [1 ,3]dioxolo[5,4-g]quinolin-7-carboxylate (3a-z, 4a-z) and similar types (5a-z), of general formula (I, II, III and IV), useful in the...  
WO/2007/046513A2
The present invention relates to a benzoylurea compound represented by formula (I), wherein X and Y represent a fluorine atom or a chlorine atom, R1 represents a lower alkyl group or the like, R2 represents a lower alkyl group, R3 repres...  
WO/2007/036572A1
The invention relates to compounds of formula (I) which contain aldimine, and to the use thereof. Said compounds which contain aldimines are characterised in that they are odour-less and during hydrolysis the odour-free aldehydes are sep...  
WO/2007/002635A3
The present invention provides novel C-linked cyclic compounds and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein...  
WO/2006/060774A3
The present invention provides compounds with activity against a variety of flaviviruses, uses thereof, and methods for identifying such compounds.  
WO/2006/052542A3
CB1 antagonists are provided. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 receptor modulation in humans, domesticated companion ani...  
WO/2007/029155A2
The present invention relates to an improved process for preparing pure celiprolol base in monohydrate form by crystallizing crude celiprolol base in one or more carboxylic acid ester solvents and its conversion to pharmaceutically accep...  
WO/2006/135694A3
Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.  
WO/2006/119713A3
The invention relates to chemical compounds which are obtained by means of in silico molecular modelling and which have a structure that can be used to block phosphorylation by interacting said compounds with the phosphorylation domain o...  
WO/2005/122379A3
The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...  
WO/2007/013811A2
The present invention in a first aspect relates to flavour modulation in foodstuffs, beverages, tobacco products and oral care products, using a flavour modulating substance selected from the group represented by formula (I), edible salt...  
WO/2007/006761A1
This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activ...  
WO/2007/002635A2
The present invention provides novel C-linked cyclic compounds and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein...  
WO/2005/015158A3
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...  
WO/2007/002639A2
The present disclosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV) , methods and intermediates for synthesizing such compounds, and methods of using the co...  
WO2006020358A3
The invention is directed to certain biphenyl compounds. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Y are as defined below, and to pharmaceutically-accep...  
WO/2006/135910A1
The invention describes novel crosslinking compounds that include photoactivatable moieties. Several families of compounds are disclosed that can include one or more hydrophilic moieties that help to solubilize the compounds in aqueous e...  
WO/2006/133588A1
It has been found that phenylurea compounds, in particular diphenylurea compounds of the formula (I), and pharmaceutically acceptable salts thereof are medicaments for the treatment of neurodegenerative diseases, in particular diseases i...  
WO/2006/135694A2
Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.  
WO/2006/131381A1
The invention relates to a method for producing N-aryl carbamates (urethanes) and N-aryl isocyanates. According to said method, aromatic nitro compounds are subjected to a reductive carbonylation in the presence of carbon dioxide and org...  
WO/2006/128670A1
The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, Rl, R2, R3, R4, R5, R6, R7, R8, R9, Rl0, RI l, R12, R13, R14, R15, R16, Rl7, R18, Rl9, R20, R21 and R22 are individuall...  
WO/2006/128268A1
The present invention describes functionalizeds derivatives of ethyl 6-N- alkyl and/or 6-N-aryl ureas [1 ,3]dioxolo[5,4-g]quinolin-7-carboxylate (3a-z, 4a-z) and similar types (5a-z), of general formula (I, II, III and IV), useful in the...  
WO/2006/126635A1
A compound represented by the general formula below or a salt thereof is a useful intermediate in the production of a [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine compound that has excellent cell adhesion inhibitory effect and cel...  
WO/2006/122788A1
The present invention provides a compound of formula (I) wherein: R1 is a group selected from -CH2OH, -NHC(O)H and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the car...  
WO/2006/122782A1
N-(2-hydroxyalkanoyl) -N, N' -dialkylureas of general formula (I) are described A-X-(A)n, where A: m = 0 or m = 1; when m = 0, X = R''', where R''' is an aliphatic, cycloaliphatic, arylaliphatic radical, C1-C18; when m = 1, X = -(CH2)n-,...  
WO/2006/122772A1
The invention relates to salts of substituted allophanates, to methods for producing them, to drugs containing said compounds and to the use of said compounds for producing drugs.  
WO/2006/122072A2
The present invention relates to processes for preparing biaryl ureas derivatives and analogs thereof. The invention also provides compounds useful as intermediates in the processes of the present invention. The process is useful for pre...  
WO2006083924A8
1-Acylamino-2-hydroxy-3-amino-?-arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.  
WO/2006/117549A1
Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intr...  
WO/2006/118071A1
In an apparatus for synthesizing urea and a method of improving the same, it becomes possible to provide a heavy condenser at a relatively low position and, further, it becomes possible to overcome the problems caused by passing a proces...  
WO/2006/118070A1
In an apparatus for synthesizing urea, it is avoided to pass downward a urea synthesis solution, which is a two-phase gas-liquid stream, and the stream is stabilized as such (i.e., as being the two-phase gas-liquid stream) to enable smoo...  
WO/2006/108712A1
The invention relates to poly-substituted tetrahydronaphtalene derivatives of formula (I) and to a method for the production and the use thereof in the form of antiphlogistics.  
WO/2006/101318A1
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The...  
WO/2006/101321A1
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The...  
WO/2006/100563A1
Methods and reagents for transition metal-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for ...  
WO/2006/092204A1
The invention relates to a new class of compounds with action inhibiting carnitine palmitoyl transferase (CPT), pharmaceutical compounds which contain at least one new compound according to the invention, and their therapeutic use in the...  
WO2006074025B1
Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring mem...  
WO/2006/089952A1
The invention relates to novel compounds of the formula (I) and their use in stabilization of Factor Vila or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof.  
WO2005107762A3
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2006/084688A1
Compounds of the formula (I): Wherein R1, R2, X and N are as defined in the specification; E is N, CH; A1 and A" are terminal groups as defined in the specification. The compounds have utility as HIV-I protease inhibitors.  
WO/2006/083924A1
1-Acylamino-2-hydroxy-3-amino-&ohgr -arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.  
WO/2006/083266A1
In accordance with the present invention, compounds having formula (I), where the variables are as identified in the claims, that inhibit Type III protein secretion have been identified, and methods for their use provided. In one aspect ...  
WO/2006/074025A1
Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring mem...  
WO/2006/069690A1
The invention relates to radiation-hardenable compounds, methods for the production thereof and the use thereof, in addition to highly scratch-resistant coating materials containing said compounds.  
WO/2006/063653A1
The invention relates to a method for producing onium salts with tetrafluoroborate anion by reacting an onium halide with an oxonium tetrafluoroborate, sulfonium tetrafluoroborate, or triphenylcarbonium tetrafluoroborate.  
WO/2006/063654A1
The invention relates to a method for producing onium alkyl sulfates by reacting an onium halogenide with a symmetrically substituted dialkyl sulfate, the alkyl group thereof containing between 1 and 14 C atoms, with an unsymmetrically s...  
WO/2006/062580A1
The invention relates to novel compounds and processes for their preparation and their use for preparing medicaments for the treatment of disorders, especially hyper-proliferative disorders.  
WO2006004613A3
The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their...  
WO/2006/052722A1
The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/o...  
WO/2006/050800A1
Compounds of formula (I), where R6, R7, R8, R9, Het1, X and X' have the meanings given in claim 1 are tyrosine kinase inhibitors, in particular, of TIE-2, and Raf kinases and can be used, amongst other things, for the treatment of tumours.  

Matches 451 - 500 out of 6,113